As we wrap up our AACR coverage, I can’t believe it’s already time to discuss the annual American Society of Clinical Oncology (ASCO) meeting already – it seems to come around way too fast.
Over the last few years, we’ve reported on the rapid and impressive rise of innate, adoptive and adaptive immunotherapies in cancer research and wondered how long it would take before we see such data presented in the plenary session. That actually happens this year… finally!
It does look like 2015 is the year that checkpoint inhibitors cannot be ignored for plenary selection with the wealth at data available at first AACR and now ASCO emerging.
This is no bad thing, especially given these drugs can affect the long tail of survival and are really starting to impact the dismal 5-year survival rates in metastatic melanoma and non-small cell lung cancer (NSCLC).
Beyond those two tumour types, what else can we expect to see and how is the data likely to shape up? We took a look at the abstracts available based on the titles only, the actual abstracts themselves come out next week.
What did we find?
You can check out our first Preview on the Top 10 immunotherapy trials with checkpoint blockade by signing up or logging in the box below…